IGC Pharma Expands Phase 2 CALMA Trial into Colombia’s Premier Alzheimer’s Research Center February 9, 2026 Read More »
IGC Pharma Reaches 70% Enrollment in Phase 2 CALMA Trial Evaluating IGC-AD1 for Alzheimer’s Agitation February 2, 2026 Read More »
